Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Moodys
McKesson
McKinsey
Johnson and Johnson

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR FERRIC CARBOXYMALTOSE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ferric Carboxymaltose

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00548691 ↗ Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients Completed American Regent, Inc. Phase 3 2007-10-01 The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
NCT00548691 ↗ Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients Completed Luitpold Pharmaceuticals Phase 3 2007-10-01 The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
NCT00548860 ↗ Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients Completed American Regent, Inc. Phase 3 2007-10-01 The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.
NCT00548860 ↗ Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients Completed Luitpold Pharmaceuticals Phase 3 2007-10-01 The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ferric Carboxymaltose

Condition Name

Condition Name for Ferric Carboxymaltose
Intervention Trials
Anemia 23
Iron Deficiency Anemia 22
Iron Deficiency 17
Iron-deficiency 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ferric Carboxymaltose
Intervention Trials
Anemia, Iron-Deficiency 81
Anemia 62
Deficiency Diseases 19
Heart Failure 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ferric Carboxymaltose

Trials by Country

Trials by Country for Ferric Carboxymaltose
Location Trials
United States 147
Germany 24
Spain 15
Canada 10
Australia 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ferric Carboxymaltose
Location Trials
Pennsylvania 13
Florida 10
Texas 9
California 8
North Carolina 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ferric Carboxymaltose

Clinical Trial Phase

Clinical Trial Phase for Ferric Carboxymaltose
Clinical Trial Phase Trials
Phase 4 45
Phase 3 44
Phase 2/Phase 3 1
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ferric Carboxymaltose
Clinical Trial Phase Trials
Completed 55
Recruiting 23
Unknown status 14
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ferric Carboxymaltose

Sponsor Name

Sponsor Name for Ferric Carboxymaltose
Sponsor Trials
Vifor Pharma 24
American Regent, Inc. 21
Luitpold Pharmaceuticals 19
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ferric Carboxymaltose
Sponsor Trials
Other 128
Industry 106
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.